Our data suggests that the combination of irinotecan, or liposomal irinotecan as described in the NAPOLI-3 trial (Wang-Gillam et al., 2019; Wainberg et al., 2023), with ME3BP-7 could improve the potency as well as address the pockets of heterogeneity with low MCT1 in pancreatic cancer (Figure 4, Figure 4—figure supplement 1). Here, SLC16A1 is linked to familial pancreatic carcinoma.